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Abstract
Introduction: Use of antiretroviral therapy (ART) during treatment of drug susceptible tuberculosis (TB) improves survival.
However, data from HIV infected individuals with drug resistant TB are lacking. Second line TB drugs when combined with
ART may increase drug interactions and lead to higher rates of toxicity and greater noncompliance. This systematic review
sought to determine the benefit of ART in the setting of second line drug therapy for drug resistant TB.
Methods: We included individual patient data from studies that evaluated treatment of drug-resistant tuberculosis in HIV-1
infected individuals published between January 1980 and December of 2009. We evaluated the effect of ART on treatment
outcomes, time to smear and culture conversion, and adverse events.
Results: Ten observational studies, including data from 217 subjects, were analyzed. Patients using ART during TB treatment
had increased likelihood of cure (hazard ratio (HR) 3.4, 95% CI 1.6–7.4) and decreased likelihood of death (HR 0.4, 95% CI
0.3–0.6) during treatment for drug resistant TB. These associations remained significant in patients with a CD4 less than 200
cells/mm3 and less than 50 cells/mm3, and when correcting for drug resistance pattern.
Limitations: We identified only observational studies from which individual patient data could be drawn. Limitations in
study design, and heterogeneity in a number of the outcomes of interest had the potential to introduce bias.
Discussion: While there are insufficient data to determine if ART use increases adverse drug interactions when used with
second line TB drugs, ART use during treatment of drug resistant TB appears to improve cure rates and decrease risk of
death. All individuals with HIV appear to benefit from ART use during treatment for TB.
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Introduction
Drug resistant tuberculosis (DR-TB) poses a threat to global
health, particularly in regions most affected by the human
immunodeficiency virus (HIV) pandemic [1]. A large burden of
DR-TB cases occur in Africa, where two-thirds of all HIV infected
individuals reside [1]. However, limited access to mycobacterial
culture and drug susceptibility testing in settings where HIV/
AIDS is most prevalent precludes accurate estimates of DR-TB in
these regions [1].
International guidelines recommend that antiretroviral therapy
(ART) be started as soon as possible after TB treatment is initiated
in patients with HIV and TB [2–6]. However, it is not clear if the
benefit of early ART extends to individuals on second-line TB
treatment regimens for DR-TB. Individuals on second line TB
drugs, particularly those with HIV, may experience more side
effects, more overlapping toxicities with ART, and have higher
rates of non-adherence with TB therapy [7]. Given that second-
line treatment may be associated with higher rates of adverse
treatment outcomes and higher default rates, evidence based
strategies are needed for the management of HIV infected
individuals with DR-TB [2,8].
We performed a systematic review of the published literature on
DR-TB in HIV infected individuals and pooled individual patient
data (IPD) from included studies. Potential factors affecting
survival, cure, default, adverse events, and treatment failure in
this population were evaluated.
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Methods
Ethics Statement
Prior to data collection, a certification of exemption was
approved by the University of Washington Institutional Review
Board (IRB). In addition, authors from included studies confirmed
that they received IRB approval from their primary institutional
affiliation.
Search and Selection of studies
These data were presented in October of 2010 to the WHO
guidelines development group following an invitation to contribute
to the 2011 update of the guidelines for programmatic manage-
ment of drug resistant tuberculosis as an evidence review team
[9,10].
We searched Medline, The Cochrane Register of Controlled
Trials, GATEWAY and Embase for articles and conference
abstracts published from January 1980 through December of 2009
as described previously [11]. We included studies that utilized an
appropriate study design (randomized control trials (RCT), quasi-
randomized controlled trials, and cohorts with a concurrent (non-
historical) comparison group), and met the following criteria: 1)
included HIV-1 infected individuals, 2) documented the use or
non-use of ART, 3) documented TB disease by a positive sputum
culture, 4) documented resistance to at least one first line drug
(rifampin, isoniazid, pyrazinamide, ethambutol), 5) documented
the use of at least one anti-tuberculosis medication other than
rifampin, isoniazid, pyrazinamide, ethambutol or streptomycin,
and 6) collected at least one of our outcomes of interest (all-cause
mortality, cure, treatment failure, default, time to smear and/or
culture negativity or adverse event). Studies performed in both
clinics and hospitals, and published in any language or geographic
location, were included. We pre-specified that should data from
the published study population be insufficient, individual patient
data (IPD) would be considered for inclusion. A representative
search strategy is shown in Appendix S1.
MA and PP independently evaluated the titles, abstracts, and
descriptor terms of all references identified in the initial search,
along with the reference lists of relevant reviews and articles, to
determine eligibility. When reviewers disagreed on eligibility,
studies were reviewed together and consensus was reached. If an
abstract was not available, the abstract was not in English, or the
discrepant decision could not be resolved based on the abstract
alone, the full text was evaluated or the author contacted to assess
eligibility.
The full text articles of all references that passed the abstract-
review stage were independently evaluated by MA and PP using a
pre-determined screening form. Data were extracted from all full
text articles by PP and MA to determine eligibility for inclusion.
Studies were reviewed for relevance based on study design,
participant characteristics, exposures and outcome measures. Risk
of bias was assessed at the outcome level after included data sets
were identified.
Because no study presented risk estimates stratified by the pre-
determined eligible participants, a decision was made to combine
individual patient data from all studies and to evaluate these data
following the Cochrane Library Guidelines on the use of
individual patient data. Eligible authors were asked to provide
baseline characteristics (age, gender), details of TB and ART
regimens including length of treatments and regimens, details of
other drug therapies (such as cotrimoxazole), and outcomes for
DR-TB/HIV co-infected study participants who had an end of
treatment outcome and whose ART status was known. In
addition, study authors were queried on whether TB treatments
were modified based on drug susceptibility patterns, and if so, if
information on specific second line TB drug regimens was
collected. If the authors were able to provide at least details on
the second line TB regimen, whether or not the patient was on
ART, and one or more outcomes, the study was included. This
systematic review was performed in accordance with the guidelines
of the preferred reporting items for systematic reviews and meta-
analysis (PRISMA) [12].
Data extraction and definitions
The following characteristics were extracted from each
included study: author, publication status, year of implementa-
tion, study design, study type, duration, completeness of follow
up, country and location of study, settings, method of recruit-
ment, and number of participants. We classified TB drugs
according to the classification used in the WHO guidelines
(Groups 1,2,3,4 and 5) [13]. Rifampin, isoniazid, pyrazinamide,
ethambutol and streptomycin were defined as first line drugs. All
other TB drugs were classified as second line drugs. ART was
defined as drugs from any of the following classes: nucleoside (and
nucleotide) reverse transcriptase inhibitors (NRTI), non-nucleo-
side reverse transcriptase inhibitors (NNRTI), protease inhibitors
(PI), and integrase inhibitors. Multidrug resistant tuberculosis
(MDR-TB) was defined as resistance to isoniazid and rifampin.
Extensively drug resistant tuberculosis (XDR-TB) was defined as
MDR-TB tuberculosis with resistance to a fluoroquinolone and at
least one second line injectable agent. Other drug resistance
(ODR-TB) was defined as TB drug resistance requiring a second
line drug, but not meeting the definition of MDR-TB. Death was
defined as all cause mortality during TB treatment. We accepted
each individual study definition of cure, default, adverse event,
treatment success, and treatment failure. Smear or culture
conversion was defined as the occurrence of smear or culture
conversion during therapy, without subsequent positive microbi-
ologic specimens during treatment. Time to smear and/or culture
conversion was defined as time to the first of three consecutive
negative smears/cultures.
Data Synthesis and Analysis
Individual patient data from all studies were treated as a single
cohort. Time to cure, death, treatment failure and default was
defined as length of treatment on second line drugs. The incidence
of each outcome reported for each intervention group and
compared using hazard ratios and 95% confidence interval (CI)
from Cox-proportional Hazards models. Time to event analysis
was used to account for between-study differences in opportunity
for an event to occur because included studies had variable lengths
of treatment and follow-up.
Incidence rates and hazard ratios for adverse events were not
calculated, as data on timing of adverse events were not available.
We instead compared the occurrence of any adverse event across
treatment groups by calculating odds ratios using a two-sided
Fisher’s exact test. To account for the disproportionate length of
follow up time between studies, we stratified analyses by follow-up
times of less than 1 year, 1–2 years, and greater than 2 years.
Specific types of adverse events were not recorded for most studies
therefore could not be assessed individually. All statistical analyses
were conducted in STATA 10.1 with statistical significance
criteria set at p#0.05.
The quality of evidence was assessed using the GRADE
approach [14]. For purposes of systematic reviews, the GRADE
approach defines the quality of a body of evidence as the extent to
which one can be confident that an estimate of effect or association
is close to the quantity of specific interest. Quality of a body of
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Figure 1. Flow diagram for study inclusion. Two authors each sent data that was represented by two included studies, therefore 12 references
actually included. 1 Lew W, Pai M, Oxlade O, Martin D and Menzies D. Initial drug resistance and tuberculosis treatment outcomes: systematic review
and meta-analysis. Ann Intern Med 2008;149:123–34. 2 Menzies D, Benedetti A, Paydar A, et al. Standardized treatment of active tuberculosis in
patients with previous treatment and/or with mono-resistance to isoniazid: a systematic review and meta-analysis. PLoS Med 2009; 6:e1000150.
Reasons for Exclusion II. Inappropriate study design (n = 34); Outcomes of interest are not measured (n = 22); Not deemed research/no data
collected (n = 18); No TB drug resistance or drug resistance testing (n = 21); No HIV+ patients or HIV-testing (n = 37); No TB-infected patients or TB
treatment (n = 4); No 2nd line drug TB therapy used (n = 16); No ART data collected (n = 3); Author contacted for another study/same patients (n = 12).
Other Reasons for Exclusion III (other n = 11): Not interested (n = 1); Inappropriate study design (n = 1); No HIV (n = 3); In process of publication
(n = 1); Already contacted (n = 5).
doi:10.1371/journal.pone.0047370.g001
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evidence involves consideration of within-study risk of bias
(methodological quality), directness of evidence, heterogeneity,
precision of effect estimates and risk of publication bias.
Heterogeneity and publication bias were only addressed in studies
that had both ART users and non-users and in whom the sample
size was greater than 10. The quality rating across studies has four
Table 1. Details of included studies.
Study Methods Participants




Prospective cohort study of HIV/TB co-
infected patients in Thailand who were
programmatically treated and followed
from May 2005- September 2006.
Of the 667 patients in the published
study, 16 (2.3%) had MDR TB and 273
(41.0%) were prescribed ART. Of
published patients, 8 (1.2%) met
inclusion criteria, 4 (50%) were on ART.
Six (75%) were classified as MDR and 2
(25%) as ODR.
Cure, treatment completion, death,
treatment failure, adverse events,





study of 184 culture confirmed MDR TB
patients hospitalized between Jan-2004
through Dec- 2006 in Germany.
Of the 187 patients, 177 (94.7%) were
classified as MDR and 7 (3.7%) as XDR.
Seven (3.7%) were HIV positive. Four
(2.1%) patients were included in the
review, all of which were on ART and
were classified as MDR.
Cure, treatment completion,
treatment success, death, failure,
treatment failure (death or failure),
default, adverse events, transfer
out, culture conversion
Cure-Laserson criteria: completed
treatment according to country
protocol and consistently
negative ($5 results) in final 12
months of therapy. Conversion-
not defined in publication
Shean,
2008
Hospital-based retrospective cohort study
in South Africa from January 1992-
December 2002.
All 491 patients included in the study
were MDR and of those tested, 15 (9%)
were HIV-infected. Twenty (4.1%)
patients were included in the review, all
of whom were on ART and all of whom
were classified as MDR.









Hospital-based cohort study in Argentina
from December 2001 to December 2003.
Of the 53 patients included in the
published study, all (100%) were
included in the review as well as 1
additional patient. Twenty-eight (51.9%)
were on ART. All patients were classified
as MDR.






Population-based cohort study in Estonia,
Germany, Italy, and the Russian
Federation between January 1999 and
January 2006
Of the 361 MDR and 64 XDR patients
included in the published study, 8 (1.9%)
patients were included in the review, all
were MDR, and all were on ART.
Cure, treatment success, death,








Population-based cohort study in Brazil
between Jan 1994 and July 2003.1
OF the 93 patients sent for possible
inclusion, 16 (17.2%) were included in
the review, 5 (31.3%) with ODR and 11
(68.8%) classified as MDR. All included
patients were on ART.




Population-based cohort study in Latvia
between January 2000 to December
2004.
Of the 1027 patients (979 MDR and 48
XDR) included in the published study, 7
(0.7%) MDR patients were included in
the review, 5 (71.4) of which were on
ART.




Population-based case-control study2 in
the US (Houston, Texas) of enrolled TB
cases between August 1995 and
September 2001.
Of the 193 patients with drug resistance
TB in the published study, 10 (0.5%)
were classified as having MDR with
remaining 183 (94.8%) patients
classified as ODR. Nine (4.7%) patients
were included in the review, all
classified as ODR and all on ART.







Retrospective cohort study of patients
diagnosed and treated at four of nine
South African hospitals designated to
treat XDR TB in South Africa between
August 2002 and February 2008.
Of the 174 XDR patients included in the
analysis, 82 (47.1%) were HIV positive
and included in the review. Of the
included patients, 52 (63%) were on
ART.
Death, culture conversion Cure-N/A. Conversion- Two
consecutively negative cultures,
collected 1 month apart, with




Population-based cohort study in the US
(San Francisco) from Jan 1982 to
December 2000.
Forty-eight cases of MDR cases were
reported, 11 (22.9%) were HIV positive.
All HIV positive cases were included in
the review, and 2(18.1%) were on ART.
Treatment response, relapse,
adverse events, death, culture
conversion, smear conversion
Cure- complete course of
treatment with microbiologic
and clinical response.
Conversion-series of 3 negative
culture/smear results
1Data from routine TB surveillance system of the TB Division State of Sao Paulo identified through 2003 thereby representing a larger study population than those
included in the referenced abstracts.
2Nested in larger cohort study, which is the design from which we pulled data.
3Cure, culture and smear conversion data not presented in publication.
doi:10.1371/journal.pone.0047370.t001
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levels: high, moderate, low or very low. The GRADE Profiler
software was used for performing the GRADE analyses.
Results
Our electronic search strategy resulted in 2777 unique citations.
We identified 110 additional citations through review of a previous
meta-analysis of studies evaluating treatment outcomes of drug
resistant TB and from contact with study authors [15]. We
identified 153 potentially relevant studies and contacted the
authors of these studies for further information. Eighty-seven
authors (57%) responded to our query and 10 individual patient
data sets from 12 citations were received for inclusion in our study
(figure 1). While all patients from one study met criteria for
inclusion in this review [16], only a subset of patients from all
other studies met criteria for inclusion. The number patients
included from each study and study details are described in table 1.
All 10 studies included death as recorded outcome [16–25].
Nine of the included studies recorded cure as a potential outcome,
although the definition of cure was variably defined [16,17,19–25].
Three studies included patients with ODR-TB [20,21,25]. Of the
16 patients with ODR, 10 had resistance to rifampin, 5 were
resistant to isoniazid in addition to a second first line drug other
than rifampin, and 1 had isoniazid monoresistance. Six of the
Table 2. Patient characteristics by ART use.
Antiretroviral Status
Characteristic Overall ART (n = 126) N1 (%)
No ART (n = 91)
N1 (%) p-value2
Male
86 (55.8) 49 (55.1) 37 (56.9) 0.82
Age (range 18–59)
,18 1 (0.5) 1(1.0) 0 0.92
18–24 14 (7.6) 7(6.9) 7(8.3)
25–29 27 (14.6) 16(15.8) 11(13.1)
30–34 67 (36.2) 34(33.7) 33(39.3)
35–44 53 (28.7) 31(30.7) 22(26.2)
45+ 23 (12.4) 12(11.9) 11(13.1)
Median (IQR) 32.9 (29.4–39.5) 33.0 (29.5–39.5) 32.1 (29.3–39.2)
CD4 count
.350 cells/ml 13 (12.5) 10(15.2) 3(7.9) 0.550
200–350 cells/ml 3 (2.9) 2(3.0) 1(2.6)
,200 cells/ml 88 (84.6) 54(81.8) 34(89.5)
Median (IQR) 55.5 (21.0–123.5) 53.5 (17–155) 56 (23–94)
TB Resistance Pattern
ODR 16 (7.4) 15(11.9) 1(1.1) 0.001
MDR 119 (54.8) 59 (46.8) 60(65.9)
XDR 82 (37.8) 52(41.3) 30(33.0)
Length of TB treatment
Median Months (IQR) 28.5 (10.8–45.8) 31.9(15.2–45.8) 22.5 (4.9–43.8) 0.008
Total Number of Drugs
, = 4 61 (28.1) 39(31.0) 22(24.2) 0.179
5 85 (39.2) 52(41.3) 33(36.3)
. = 6 71 (32.7) 35(27.8) 36(39.6)
Total Number of Effective Drugs3
, = 3 185 (85.3) 112 (88.9) 73(80.2) 0.185
4 22 (10.1) 10(7.9) 12(13.2)
.4 10 (4.6) 4(3.2) 6(6.6)
ART Regimen Base
NNRTI – 60(51.3) – –
PI – 26 (22.2) – –
NRTI – 31 (26.5) – –
1N’s may not add up to total N because of missing values.
2p-values of ART use vs. non-use comparisons based on the categorical version of variable are presented unless interpretation of p-value based on of continuous version
differed.
3Effective drug: Demonstrated susceptibility to drug by sputum culture.
doi:10.1371/journal.pone.0047370.t002
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eight studies which included patients with MDR-TB defined cure
according to the recommended criteria (five or more negative
cultures in the final year of treatment) [16,19,20,22–24,26] while
other studies defined cure as having two negative cultures in the
final month of therapy and a documented clinical response. In the
single study including individuals with XDR-TB, cure was not
documented [18]. Data on smear or culture conversion were
available from six studies [17–20,23,24]. Default was documented
in nine studies and was defined differently across studies. Adverse
events were recorded in six studies, although the type of adverse
event, the organ system involved, or the severity of the event was
not recorded in most studies [16,17,19,21,24,25]. Treatment
failure was documented in only one patient and was not evaluated
as an outcome.
A total of 217 patients were included in our analysis. Included
individuals represent a diverse geographic population, with the
majority from Africa (47%) and South America (32%). Charac-
teristics of included study participants are shown in table 2.
Slightly more than half of all included individuals were male (56%)
and most (71%) were between 25 and 44 years of age. Among
patients with CD4 count data available at the start of ARV
treatment (50% of all included participants), 45% had a CD4
count ,50 cells/mm3, 85% had CD4 counts ,200 cells/mm3,
3% had CD4 counts between 200 and 350 cells/mm3, and 13%
had CD4 counts $350 cells/mm3. All individuals were being
treated for pulmonary TB and more than half (59%) were
receiving ART. In the minority of cases (9 patients) the ARV
regimen was not known. In the remaining patients, the reasons for
choice of ARV regimen were not given and regimens varied
widely. No patients were recorded to have received monotherapy
for HIV, 4 patients were recorded to have received 2 drug ARV,
and the remaining 113 patients received 3 drug ARV. As noted in
Table 2, 60 patients received a regimen which included 1 or more
non-nucleoside reverse transcriptase inhibitors (NNRTIs), 31
received a regimen with 1 or more nuceloside reverse transcriptase
inhibitors (NRTIs), and 26 received a regiment with 1 or more
protease inhibitors (PIs). Data on timing of ART initiation relative
to TB treatment was available for 17 (8%) patients. While MDR-
Figure 2. Kaplan Meier Curve for survival comparing ART vs. no ART among all-patients (N = 216). Note: 1 additional death occurred at
month 37.
doi:10.1371/journal.pone.0047370.g002
Table 3. Association predictors and death, cure, culture conversion, and smear conversion.
Death Cure Culture Conversion Smear Conversion
Unadjusted Adjusteda Unadjusted Adjusteda Unadjusted Adjusted1 Unadjusted Adjusted2
HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI)
ART use vs.
non use
0.38(0.25, 0.58) 0.39 (0.26, 0.61) 3.40 (1.56–7.40) 2.32 (1.02–5.28) 1.04 (0.61, 1.80) 1.61 (0.79–3.27) 2.21 (0.97–5.04) –
CD4 count 0.56 (0.37, 0.86) 0.56 (0.35–0.90) 1.10 (0.92–1.32) 0.94 (0.75–1.19) 1.00 (0.89–1.11) 1.00 (0.89–1.14) 0.90 (0.63–1.30) –
Age 1.02 (0.89–1.17) 1.01 (0.89–1.16) 0.94 (0.75–1.19) 0.98 (0.76–1.26) 1.04 (0.88–1.23) 1.07 (0.91, 1.26) 1.03 (0.83–1.29) –
Female vs.
male
1.09 (0.64–1.85) 0.96 (0.56–1.64) 0.75 (0.29–1.94) 0.96 (0.35–2.66) 0.54 (0.29–1.00) 0.67 (0.36–1.28) 0.60 (0.24–1.47) –
1Adjusted for TB resistance pattern as indicator variables.
2Adjustment not possible because less than 6 patients with ODR and none with XDR.
doi:10.1371/journal.pone.0047370.t003
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TB was common (55%), 38% of included individuals were
classified as having XDR-TB and 7% with ODR-TB. The
median length of TB treatment was 28.5 months (IQR: 10.8–45.8
months). All patients received 4 or more anti-tuberculosis drugs
during the intensive phase of treatment.
Ninety-one patients (42%) died during TB treatment (incidence
rate (IR): 434 per 1000 person years (PY)). ART users were less
likely to die than ART-non-users (HR: 0.38, 95% CI 0.25, 0.58)
(Table 3 & Figure 2) and the median time to death was
significantly shorter among ART non-users (11 months) than
among ART users (37 months). The association between ART use
and survival did not change after adjustment for TB resistance
pattern categorized as ODR, MDR, and XDR. The benefit of
ART use in reducing risk of death was more pronounced in
patients with CD4 counts ,200 cells/mm3 (HR: 0.24 (95%CI:
0.14, 0.43) and greatest in magnitude among the 47 patients with
CD4 counts ,50 cells/mm3 (HR: 0.15; 95%CI: 0.06, 0.38). A risk
estimate describing the association between ART use and death
among those patients with CD4 counts $350 cells/mm3 could not
be estimated due to only 1 death occurring among an ART user.
Approximately one-third of patients (40/134) met the individual
study’s criteria for cure at the end of treatment (incidence rate of
292 per 1000 PY). Cure was more common in ART users
compared to non-users (HR of for cure: 3.4, CI: 1.6, 7.4) (Table 3
& Figure 3). The magnitude of the association between ART use
and likelihood of cure was greater among individuals with CD4
counts ,200 cells/mm3 (HR: 7.44, 95% CI: 1.13, 48.9) as
compared to those with CD4 counts $350 cells/mm3 (HR: 2.66,
95%CI: 0.45, 15.8). However there was not statistical evidence of
effect modification by CD4 count (likelihood ratio test p = 0.22).
After adjusting for TB resistance pattern, ART use remained
associated with a greater likelihood of cure (aHR: 2.3 (1.0, 5.3).
Fifty-two of 121 participants (41%) with culture conversion data
available had documented conversion to negative during treat-
ment while 26 (72%) of those with data available converted their
smear to negative during treatment. There was no statistically
significant association between ART use and earlier time to
culture conversion (aHR: 1.86, 95%CI: 0.98, 3.56) or smear
conversion (HR: 2.21, 95%CI: 0.97, 5.04).
Default during treatment occurred in 15 (11%) of the 134
participants with data available. Default was not associated with
ART use among all included participants, although among individuals
with CD4 cell counts ,200 cells/mm3, ART users did appear less
likely to default (HR: 0.26, 95%CI: 0.07, 0.93). Among the 120
individuals with adverse event data, almost a third (28%) had an
adverse event recorded: 19 (31%) participants using ART and 15
(25%) of participants not using ART (p = 0.55). Data on severe adverse
events were limited, however one of the 19 individuals with an AE
while using ART had a documented change in treatment and 4 of the
15 individuals with an AE not using ART had a change in treatment.
Among patients followed up for ,1 year, 7.7% of ART users had any
adverse event whereas 26.3% non-users had an adverse event reported.
Conversely, among patients followed for 1 or more years, 48% of ART
users had an adverse event reported and 23.8% non-users (p = 0.10).
Discussion
While large randomized controlled trials of drug susceptible TB
using first line anti-tuberculosis drugs have demonstrated survival
benefit with the use of ART, similar trials amongst HIV infected
individuals with drug resistant tuberculosis are lacking [2]. The
results of this analysis suggests that ART increases survival and
results in higher rates of TB cure in HIV infected individuals with
drug resistant tuberculosis. In addition, ART does not appear to
impact frequency of adverse drug reactions or result in higher rates
of default from TB treatment programs in these individuals. ART
appears to benefit all HIV infected individuals during treatment
for tuberculosis.
In this analysis, the benefit of ART among HIV infected
individuals with DR-TB was seen across all levels of immunosup-
pression, although the benefit was most pronounced among those
with CD4 counts ,50 cells/mm3. This finding supports current
WHO recommendations to start ART in subjects with HIV and
drug resistant tuberculosis irrespective of CD4 count [9].
Figure 3. Kaplan Meier Curve for cure comparing ART vs. no ART among all-patients (N = 216). Note: 1 additional cure event occurred at
month 60.
doi:10.1371/journal.pone.0047370.g003
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Table 4. Overlapping toxicities of anti-tuberculosis drugs and ARV.
Potential Toxicity Antiretroviral Therapy Antituberculosis Therapy



























gastro-intestinal intolerance zidovudine ethionomide/prothionomide






bone marrow toxicity zidovudine linezolid
rifampin (thrombocytopenia)
lactic acidosis stavudine linezolid
didanosine
zidovudine
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The benefit in survival and cure observed in this analysis may be
due to several mechanisms. First, It is possible that the impact of
ART on TB treatment outcomes is due to the survival benefit of
ART in HIV infected individuals. ART increases survival through
a number of pathways, including a reduction in risk of new
opportunistic infections and a reduction in AIDS defining illness
[27–31]. This effect of ART on survival is strongest among
individuals with lower CD4 counts [3,4]. If HIV infected
individuals on ART survive longer, they will have greater
opportunity for cure.
It is also likely that the immune reconstitution observed
following initiation of ART impacts the control and clearance of
TB [32]. The recovery of circulating T cells capable of producing
interferon gamma and other Th1 cytokines following the initiation
of ART may directly result in improved immune responsiveness, a
more robust granulomatous response, and an increase in
mycobacterial killing and containment [33].
The increased rates of survival and cure observed may also be
the results of the impact of ART on retention into care. Individuals
enrolled into ART care are required to make frequent visits to
health care facilities and early initiation of ART in patients being
treated for TB has been shown to improve retention to completion
of TB treatment [34].
Second line treatment options for TB can involve the use of
multiple drugs, which may have overlapping potential toxicities
with available ART (table 4) [35,36]. The use of ART in
combination with TB drugs also increases pill burden, potentially
resulting in lower rates of compliance [37,38]. In this analysis, we
report that the overall risk of adverse events was not higher in
individuals who received ART when compared to those who did
not receive ART. It is important to note that this analysis had
limited power to detect differences in adverse events between
individuals stratified by type of ART use. This may be important
when considering particular combinations of ARV/SLD, such as
tenofovir and group 2 TB drugs, which have overlapping
toxicities. In addition, the lack of a common definition of an
adverse event across studies and lack of documentation of time to
an adverse event further limited this analysis.
We found ART use was associated with a trend toward
increased smear conversion and a shorter time to conversion.
Given that second line TB regimens may be less effective at
clearing TB infection, this finding suggests that ART may provide
some additive benefit in reducing bacillary load in these patients
[39]. If confirmed, ART may be an important adjunct to
appropriate infection control by reducing smear positivity in areas
with high rates of drug resistance and TB/HIV co-infection.
Strengths of this systematic review include the relatively large
number of individuals included in the pooled analysis. In addition,
the analysis was performed according to published guidelines for
systematic reviews. However, there are a number of limitations. The
inclusion of observational studies may have resulted in selection bias
by selecting individuals for ART who were presumed to be more
compliant. These individuals would have more frequent contact
with health care providers as a result of being on ART, and
subsequently more opportunity for diagnosis and management of
health issues. ART therefore may be a surrogate for increased access
to care and improved compliance with treatment. Ideally, we would
perform a comprehensive analysis of statistical heterogeneity across
studies. However, meta-regression requires that effect size be
estimated within each study. Because some studies contributed a
very small number of patients, or only contributed a subset of
patients either on or off ART, within-study effect estimates were not
possible for all studies. However, when we did an analysis of the
subset of studies with sufficient sample size [16,18] we found
homogeneity in survival estimates. We were also unsuccessful in
contacting 43% of authors with potential data for this analysis. In
addition, we may have failed to identify other sources of data due to
publication bias. Significant heterogeneity was observed in the
outcomes measured and in the definition of recorded outcomes.
This resulted in few individuals being included in the analyses of
some outcomes of interest, which limited our power to evaluate
many of these outcomes. Lastly, three randomized controlled trials
evaluating ART timing and use in TB cases were published after
our search strategy was employed [2,4,6]. Although these studies
enrolled mostly drug sensitive TB patients, the data from drug
resistant TB patients could have improved the GRADE quality of
the studies. limitations contributed to a very low quality of GRADE
evidence for the early initiation of ART in all subjects with drug
resistant tuberculosis [10].
Despite these limitations, the results of this analysis suggest a
benefit of ART use in patients with drug resistant TB and HIV [9].
This analysis has highlighted important gaps in the literature
regarding the optimal management of drug resistant TB in HIV
infected patients. Prospective studies comparing different ART
regimens in individuals with drug resistant tuberculosis requiring
second line anti-tuberculosis drugs are needed. In addition, HIV
infected individuals should be included in trials evaluating new anti-
tuberculosis drugs and regimens for drug resistant tuberculosis [40].
Given that a substantial proportion of drug resistant TB is emerging
among HIV infected individuals, optimal treatment strategies are
needed to direct the management of these individuals.
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